Smartphone-enabled fluorescence platform offers accessible detection of Alzheimer's amyloid-β biomarker
核心洞察
Scientists at JNCASR developed a fluorescence lifetime-responsive probe, TZ-48 (搜索), that selectively detects amyloid-β (搜索) fibrils through turn-on fluorescence and distinct lifetime signatures.
TZ-48 (搜索) demonstrates blood-brain barrier permeability, labels Aβ plaques in transgenic AD mouse brains, and detects Aβ in cerebrospinal fluid and blood serum.
The ADxFluor smartphone-integrated platform quantifies serum Aβ load, enabling a portable, low-cost, point-of-care diagnostic approach for Alzheimer's disease (搜索).
A novel smartphone-enabled platform employing a fluorescence-responsive tiny molecule as a probe offers a simple, cost-effective, and accessible approach for detecting the Alzheimer's disease (搜索) (AD) biomarker amyloid-β (搜索) (Aβ). Scientists at the Jawaharlal Nehru Centre for Advanced Scientific Research (搜索) (JNCASR), an autonomous institute of the Department of Science and Technology, developed the technology, which combines a fluorescent probe called TZ-48 (搜索) with a smartphone-integrated system named ADxFluor.
Alzheimer's disease (搜索) is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioural impairment. Central to its pathology is the misfolding and aggregation of amyloid-β (搜索) (Aβ), which self-assembles into fibrils and deposits as extracellular plaques that trigger neurotoxic cascades leading to synaptic dysfunction and neurodegeneration. The National Institute on Aging-Alzheimer's Association (NIA-AA) framework identifies Aβ, tau, and neurodegeneration as core biomarkers for definitive AD diagnosis across brain, cerebrospinal fluid (CSF), and blood. Aβ pathology is an early and AD-specific biomarker, making Aβ a more reliable diagnostic indicator.
Limitations of Current Diagnostic Approaches
Although positron emission tomography (PET) and magnetic resonance imaging (MRI) provide valuable diagnostic information, their high cost, need for specialized infrastructure, technical expertise, and limited accessibility restrict widespread use. Blood-based assays targeting Aβ and tau have emerged as promising alternatives, but are expensive and complex. These limitations highlight the need for simple, sensitive, scalable diagnostic platforms capable of early and accurate detection of Aβ for AD diagnosis.
A Fluorescence Lifetime-Responsive Probe
Fluorescence lifetime imaging microscopy (FLIM) has emerged as a powerful sensing modality because fluorescence lifetime is largely independent of probe concentration and photobleaching, enabling robust detection of biomarkers and enhancing diagnostic precision. The JNCASR team designed TZ-48 (搜索) as a fluorescence lifetime-responsive probe capable of highly selective, sensitive, and differential detection of Aβ fibrils (Aβf) through turn-on fluorescence and distinct lifetime signatures.
Published in the journal ACS Chemical Neuroscience, the research showed that TZ-48 (搜索) exhibits excellent blood-brain barrier (BBB) permeability, robust labelling of Aβ plaques in transgenic AD mouse brains, and compatibility with confocal laser scanning microscopy (CLSM) and FLIM for quantitative mapping of Aβ burden across disease stages. Beyond tissue imaging, TZ-48 enables sensitive detection of Aβ in CSF and blood serum, accurately distinguishing AD from healthy mice.
The ADxFluor Smartphone Platform
To facilitate clinical translation, the team of scientists consisting of Krithi K. Bhagavath, Madhu Ramesh, Yogendra Kumar, Sabyasachi Mandal, Hiriyakkanavar Ila and Thimmaiah Govindaraju developed ADxFluor, a smartphone-integrated platform that leverages the fluorescence response of TZ-48 (搜索) for rapid, unbiased quantification of serum Aβ load. Upon interaction with Aβ, TZ-48 undergoes changes in fluorescence intensity, which are captured and quantified using a dedicated smartphone application, enabling rapid and user-friendly detection with potential applications in the screening and staging of AD.
The system combines dual-mode brain imaging, biofluid detection, and smartphone-based quantification of Aβ in biofluids, establishing it along with ADxFluor as a foundation for next-generation smart diagnostics for AD and other neurodegenerative diseases. The integration of TZ-48 (搜索) with the smartphone-based ADxFluor platform further establishes a portable, low-cost, and user-friendly point-of-care diagnostic system, representing a significant technological and translational innovation in AD diagnostics.
Preclinical Status and Next Steps
While the findings represent a promising technological advance, the work remains at the research and preclinical stage. Further validation in human clinical studies would be required to establish its diagnostic performance and determine whether the technology can be translated into routine point-of-care Alzheimer's disease (搜索) screening.